Drug resistance and disease recurrence are important concerns for the treatment of ovarian cancer. The mechanisms underlying chemosensitivity of ovarian cancer cells remain elusive. Relapsed ovarian cancer is incurable, and there is no universal accepted therapeutic regime for patients. In this study, we demonstrate that iASPP is overexpressed in ovarian cancers, highlighting its relationship with chemoresistance and prognosis. The data presented in this study supports iASPP as a potent predictor for paclitaxel resistance. Importantly, the association of iASPP with mitotic catastrophe provides a more rational therapeutic target, which could allow the future development of cancer intervention, particularly for recurrent patients. Conversely, overexpressed iASPP inhibited apoptosis in a p53-dependent mode.
Introduction
Ovarian cancer is the most lethal gynecologic cancer worldwide because it is frequently diagnosed at advanced stage and demonstrates high rates of chemoresistance especially in patients with recurrent diseases (1) (2) (3) . For decades, a combination of paclitaxel and carboplatin has been used as the first-line chemotherapy for ovarian cancer. Although apoptosis is usually regarded as the major mechanism of cell death in response to paclitaxel (4) (5) (6) (7) , another form of cell death known as mitotic catastrophe has been observed in a wide range of human cancers treated with paclitaxel (5) (6) (7) (8) (9) . Mitotic catastrophe is a distinctive form of cell death related to abnormal mitosis, but a generally accepted definition is lacking. The morphology of cells undergoing mitotic catastrophe is initially characterized by asymmetric chromosomal condensation and missegregation, followed by formation of nuclear envelops and multi-nucleated giant cells in later stage (10) (11) (12) (13) (14) . On the other hand, cytoplasmic condensation and nuclear pyknosis are hallmarks of apoptosis (12) .
Previous reports have provided several hypotheses on paclitaxel resistance, but most of these studies focused on apoptosis caused by paclitaxel (15, 16) . The relationship between paclitaxel resistance and mitotic catastrophe in cancers is still not fully Members of the ASPP (the ankyrin repeat, SH3 domain and proline-rich region containing protein) family have been recently identified as specific regulators of p53-mediated apoptosis (17) (18) (19) . Among them, inhibitory member of the ASPP family (iASPP, encoded by PPP1R13L in human) is considered to be an oncoprotein and is overexpressed in breast cancer (20) and acute leukemias (21) . Moreover, increased iASPP confers resistance to apoptosis induced by UV radiation or exposure to cisplatin in human osteosarcoma cells and breast cancer cells (20) . The mechanism by which iASPP is overexpressed is unclear but is unlikely to be directly due to p53 inhibition (22) .
In the present study, we provided the first experimental evidence that iASPP is upregulated in ovarian cancers in relation to gene amplification and clinicopathological parameters. This study also highlighted the role of iASPP in chemoresistance to paclitaxel via its effect on mitotic catastrophe.
Material and Methods
Clinical samples and cell lines. One hundred and forty cases of archival formalin-fixed paraffin-embedded tissues, including 10 Queen Mary Hospital, the University of Hong Kong. Among the patients with cancer, 96 have been treated with chemotherapy. Patients were considered chemoresistant if they did not achieve complete response or recurred within 6 months from the last chemotherapy regimen. Patients were considered chemosensitive if they remain in remission or recurred more than 6 months after the last therapy (23) . Paired snap frozen samples of ovarian cancers and their corresponding normal tissues from another 36 patients with ovarian cancers were also collected for total RNA and genomic DNA extractions. These frozen blocks have been histologically reviewed and microdissected to ensure that the carcinoma constitutes to at least 80% of the samples.
The normal tissues were mainly obtained from the ampulla and fimbria of the Immunohistochemistry was performed using EnVision_Dual Link System (K4061;
Dako, Carpinteria, CA) with standard procedures as previously described (25, 26) .
Immunoblotting and immunofluorescence were performed as previously described (27) . Antibodies used in this study were summarized in supplementary Table 2 . The specificity of the anti-iASPP antibody used for this study was illustrated by using immunoblot in clinical samples (supplementary Figure 1B) . Omission or replacement of the primary antibody with PBS was used as a negative control. For immunoreactivity evaluation, both intensity and percentage of immunoreactivity of each section were semi-quantitated. Briefly, the level of intensity was recorded as 0 (negative), 1 (weak), 2 (mild), 3 (moderate), and 4 (strong). The percentage of positive staining was rated as 0 (<5%), 1 (6% to 25%), 2 (26% to 50%), 3 (51% to 75%), and 4 (>75%). The final immunoreactivity score was determined as a product of the two parameters, giving the range of 0 to 16.
Research. were generated and selected using G418 (8mg/ml). Transient transfections were were served to estimate the survival probability and multivariate survival analysis. P value <0.05 was considered as critical significant.
Results
Overexpression of iASPP in ovarian cancers correlates with poor survival. The expression of iASPP in ovarian benign and borderline tumors as well as invasive cancers were evaluated (supplementary Table 1 
were also examined by qRT-PCR. None of them showed significant alterations in expression levels (data not shown). Taken together, our results suggest that iASPP might affect the expression of separase via securin and cyclin B1/CDK1 complex at the protein level.
Discussion
In this study, we demonstrated upregulation of iASPP expression in ovarian cancers in vivo and ovarian cancer cell lines at both mRNA and protein levels. Furthermore, high iASPP expression level was significantly correlated with chemoresistance, shorter overall survival and disease-free survival. Multivariate analysis indicated that high iASPP expression could serve as a prognostic indicator that was independent of clinical stage, grade, histological subtype and chemosensitivity in ovarian cancers.
These observations suggest that iASPP may play a role in ovarian carcinogenesis, predict the patients' outcome and are likely to exert an effect on chemosensitivity.
To investigate the mechanism of iASPP up-regulation, the relative copy number of iASPP (PPP1R13L, chromosome 19q13.3), a gene located within the previously reported 19q amplicon of ovarian cancers, was determined (36) . Our data revealed that half of the cancers demonstrated gene amplification of iASPP, and increased mRNA expression was significantly correlated with its gene amplification. This is the first report on iASPP gene amplification in human cancers.
We next sought to investigate the effect of iASPP on chemotherapy in vitro.
Concurring with previous reports on other human malignancies (36) , we demonstrated Unlike apoptosis, the process of mitotic catastrophe is still controversial. Two mechanisms have been considered to be crucial for mitotic catastrophe, namely G2/M checkpoint and mitotic spindle checkpoint (38) . For G2/M checkpoint, abolishment of genes such as p53, p21
Cip1 and 14-3-3Sigma (39, 40) were found to promote DNA damage-induced mitotic catastrophe. It was therefore logical to speculate that iASPP may prevent paclitaxel-mediated mitotic catastrophe via p53 (20, 41) . But our findings on OVCAR3 and SKOV-3, two cell lines with dysfunction and deletion of p53 respectively, that iASPP could still inhibit mitotic catastrophe suggest otherwise.
However, further investigation is needed to understand how this p53 independent mitotic catastrophe inhibition was mediated. Nevertheless, our work does provide the first experimental evidence that iASPP plays a pivotal role in mitotic catastrophe in a p53-independent manner.
Separase is a cysteine protease and regarded as a central downstream target of mitotic spindle checkpoint (42) . The proteolytic activity of separase is regulated by at least two mechanisms (43) . Securin has long been appreciated as a direct inhibitor of separase, and cell division cycle 2 (also known as CDK1)/cyclin B1 complex Furthermore, siRNA silencing of separase was found to promote the mitotic catastrophe, which was overcome by overexpressed iASPP. However, we have only begun to understand the function of iASPP, further research on this versatile protein and its interaction with separase, securin and/or cyclin B1 is necessary.
On the other hand, recent studies demonstrated the contribution of drug transporters as important mechanisms of chemoresistance in ovarian cancer (44, 45) .
For example, as a primary efflux transporter, P-glycoprotein-mediated drug efflux could contribute to chemotherapy failure (45) . To our best knowledge, there has been no report about the relationship between iASPP and drug transporters. Further delineation of the mechanisms would be examined in our future studies.
In summary, iASPP was found to exert a powerful effect on paclitaxel resistance in ovarian cancers, since it could inhibit both mitotic catastrophe and apoptosis irrespective of p53 function. Our findings highlight the great potential of iASPP to be regarded as a biomarker for paclitaxel chemosensitivity and clinical prognosis in ovarian cancer, as well as an effective chemotherapeutic target. 
